Spontaneous coronary artery dissection (SCAD) has emerged as an important
cause of acute coronary syndrome, myocardial infarction, and sudden death,
particularly among young women and individuals with few conventional
atherosclerotic risk factors. Patient-initiated research has spurred increased
awareness of SCAD, and improved diagnostic capabilities and findings from large
case series have led to changes in approaches to initial and long-term
management and increasing evidence that SCAD not only is more common than
previously believed but also must be evaluated and treated differently from
atherosclerotic myocardial infarction. High rates of recurrent SCAD; its
association with female sex, pregnancy, and physical and emotional stress
triggers; and concurrent systemic arteriopathies, particularly fibromuscular
dysplasia, highlight the differences in clinical characteristics of SCAD
compared with atherosclerotic disease. Recent insights into the causes of,
clinical course of, treatment options for, outcomes of, and associated
conditions of SCAD and the many persistent knowledge gaps are presented.
This contribution is being co-published in the following journals: Journal of Hypertension and Vascular Medicine. There will be minor differences in the version published in Vascular Medicine due to copy-editing differences.
Abstract-Endothelial dysfunction in vascular disease states is associated with reduced NO bioactivity and increased superoxide (O 2 ⅐Ϫ ) production. Some data suggest that an important mechanism underlying endothelial dysfunction is endothelial NO synthase (eNOS) uncoupling, whereby eNOS generates O 2 ⅐Ϫ rather than NO, possibly because of a mismatch between eNOS protein and its cofactor tetrahydrobiopterin (BH4). However, the mechanistic relationship between BH4 availability and eNOS coupling in vivo remains undefined because no studies have investigated the regulation of eNOS by BH4 in the absence of vascular disease states that cause pathological oxidative stress through multiple mechanisms. We investigated the stoichiometry of BH4 -eNOS interactions in vivo by crossing endothelialtargeted eNOS transgenic (eNOS-Tg) mice with mice overexpressing endothelial GTP cyclohydrolase 1 (GCH-Tg), the rate-limiting enzyme in BH4 synthesis. eNOS protein was increased 8-fold in eNOS-Tg and eNOS/GCH-Tg mice compared with wild type. The ratio of eNOS dimer:monomer was significantly reduced in aortas from eNOS-Tg mice compared with wild-type mice but restored to normal in eNOS/GCH-Tg mice. NO synthesis was elevated by 2-fold in GCH-Tg and eNOS-Tg mice but by 4-fold in eNOS/GCH-Tg mice compared with wild type. Aortic BH4 levels were elevated in GCH-Tg and maintained in eNOS/GCH-Tg mice but depleted in eNOS-Tg mice compared with wild type. Aortic and cardiac O 2 ⅐Ϫ production was significantly increased in eNOS-Tg mice compared with wild type but was normalized after NOS inhibition with N-nitro-L-arginine methyl ester hydrochloride (L-NAME), suggesting O 2 ⅐Ϫ production by uncoupled eNOS. In contrast, in eNOS/GCH-Tg mice, O 2 ⅐Ϫ production was similar to wild type, and L-NAME had no effect, indicating preserved eNOS coupling. These data indicate that eNOS coupling is directly related to eNOS-BH4 stoichiometry even in the absence of a vascular disease state. Endothelial BH4 availability is a pivotal regulator of eNOS activity and enzymatic coupling in vivo. Key Words: endothelial nitric oxide synthase Ⅲ tetrahydrobiopterin Ⅲ nitric oxide Ⅲ superoxide N itric oxide (NO), produced by endothelial NO synthase (eNOS) in the vascular endothelium, is a critical signaling molecule in vascular homeostasis. 1 NO serves as an endothelium-derived relaxing factor, regulates vasomotor tone and blood pressure, 1,2 and has multiple antiatherogenic roles by inhibiting vascular smooth muscle cell proliferation, platelet aggregation, and leukocyte adhesion. 1 Loss of NO bioavailability is a key feature of endothelial dysfunction in vascular disease states such as hypertension, diabetes, and atherosclerosis. Furthermore, impaired NO-mediated endothelial function is an independent risk factor for cardiovascular disease. [3][4][5] Several factors contribute to loss of NO bioavailability, including reduced NO synthesis and NO scavenging by reactive oxygen species (ROS). 6 Under physiological conditions, there is a balance between endothelial NO and R...
Regular physical exercise has beneficial effects in many human disease states, including cardiovascular diseases, cancer, and depression. Exercise training of genetically modified mouse models may provide insight into the molecular mechanisms that underlie the beneficial effects of exercise. Presently, there is relatively little understanding of the normal physiology of mouse exercise. In this paper, we describe a novel computerized voluntary wheel-running system capable of recording and analyzing individual wheel rotations. Using this system, we demonstrate that C57BL/6 mice run considerable distances during the night in short bouts and at a preferred speed: the cruising speed. We find that the vast majority of running occurs around this cruising speed, which is close to the maximum speed at which the animal can run but is significantly higher than the average speeds recorded by simple digital odometers. We describe how these parameters vary with exercise training and demonstrate marked sex differences in the patterns of voluntary exercise. The results of this study have important implications for the design and interpretation of both voluntary and forced exercise experiments in mouse models. The novel parameters described provide more physiological quantitative measures of voluntary exercise activity and training and will extend the physiological utility of exercise training as a phenotyping tool in genetic mouse models.
Abstract-Vascular disease states are associated with endothelial dysfunction and increased production of reactive oxygen species (ROS) derived from vascular NADPH oxidases in both vascular smooth muscle cells (VSMCs) and endothelial cells. Recent evidence suggests an important role for VSMC NADPH oxidases in vascular ROS production. However, it is unclear whether increased NADPH oxidase activity in endothelial cells alone is sufficient to alter overall vascular ROS production and hemodynamics. We sought to address these questions using transgenic mice with endothelialtargeted overexpression of the catalytic subunit of NADPH oxidase, Nox2. Aortas of Nox2 transgenic (Nox2-Tg) mice had increased total Nox2 mRNA and protein levels compared with wild-type littermates. Both p22phox mRNA and protein levels were also significantly elevated in Nox2-Tg aortas. Aortic superoxide production was significantly increased in Nox2-Tg mice compared with wild-type, but this difference was abolished by endothelial removal. Superoxide dismutase inhibition increased superoxide release and levels of Mn superoxide dismutase protein were significantly elevated in aortas from Nox2-Tg mice compared with wild type. Increased ROS production from endothelial Nox2 overexpression led to increased endothelial nitric oxide synthase protein and extracellular signalregulated kinase 1/2 phosphorylation in transgenic aortas. Basal blood pressure was similar, however the pressor responses to both acute and chronic angiotensin II administration were significantly increased in Nox2-Tg mice compared with wild type. These results demonstrate that endothelial-targeted Nox2 overexpression is sufficient to increase vascular NADPH oxidase activity, activate downstream signaling pathways, and potentiate the hemodynamic response to angiotensin II, despite compensatory increases in vascular antioxidant enzymes. Endothelial cell Nox2-containing NADPH oxidase plays an important functional role in vascular redox signaling.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.